These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 8262586

  • 1. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ.
    Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 5. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
    Agarwal MB, Gupte SS, Vasandani D, Viswanathan C, Puniyani RR, Ramanathan J, Massil DE, Shah S, Rajyadhyaksha GC, Bhave AA.
    J Assoc Physicians India; 1991 Sep 12; 39(9):669-72. PubMed ID: 1814897
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 12; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ.
    Blood; 1992 Aug 01; 80(3):593-9. PubMed ID: 1638018
    [Abstract] [Full Text] [Related]

  • 13. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
    Kontoghiorghes GJ.
    Drugs Today (Barc); 2001 Jan 01; 37(1):23-35. PubMed ID: 12783095
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 01; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 18. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
    Curr Med Chem; 2004 Aug 01; 11(16):2161-83. PubMed ID: 15279556
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.